Cite
Müller V, Banys-Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6):100299doi: 10.1016/j.esmoop.2021.100299.
Müller, V., Banys-Paluchowski, M., Friedl, T. W. P., Fasching, P. A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO open, 6(6), 100299. https://doi.org/10.1016/j.esmoop.2021.100299
Müller, V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program." ESMO open vol. 6,6 (2021): 100299. doi: https://doi.org/10.1016/j.esmoop.2021.100299
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021 Nov 25;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25. PMID: 34839105; PMCID: PMC8637493.
Copy
Download .nbib